Last checked at 7 Apr 2020 11:41
Oncimmune Holdings plc
("Oncimmune" or the "Company")
PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, has been notified that Matthew Hall, PDMR and Chief Financial Officer, has purchased 9,487 ordinary shares of £0.01 each in the Company ("Ordinary Shares") for £0.527 per share on 7 April 2020.
Following this transaction, Matthew has a total interest in the Company of 9,487 Ordinary Shares, representing approximately 0.01 per cent of the Company's issued Ordinary Share capital.
This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Matthew Hall | |||
2
| Reason for the notification | ||||
a)
| Position/status
| Chief Financial Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Oncimmune Holdings plc | |||
b)
| LEI | 213800HCYIWT6YPI1I02 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each
| |||
Identification code | ISIN: GB00BYQ94H38 | ||||
b)
| Nature of the transaction
| Purchase of shares | |||
c)
| Price(s) and volume(s) | ||||
Price | Volume | ||||
£0.527 | 9,487 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | Same as above | ||||
- Price | |||||
e)
| Date of the transaction
| 7 April 2020 | |||
f)
| Place of the transaction | London stock exchange, AIM | |||
For further information:
Oncimmune Holdings plc
Andrew Stewart, General Counsel and Company Secretary
contact@oncimmune.com